It has been reported that, hyperglycaemia is more common in patients with coronavirus disease 2019 (COVID-19). COVID-19, which triggered by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), can cause extrapulmonary symptoms such as diabetes mellitus (DM) and hyperglycaemia, which both indicate a poor prognosis and a higher chance of death.SARS-CoV-2 infects the pancreas through angiotensin-converting enzyme 2 (ACE2), which is abundantly expressed in the pancreas relative to other organs, causing pancreatic damage, insulin secretion impairment, and hyperglycemia in non-DM patients. Thus, the present study provides an overview of the potential association or relation or linkage between COVID-19 and hyperglycemia as a risk factor for the development of diabetes mellitus in relation to diabetes pharmacotherapy.